Product Details
| Product Name:
Naxitamab |
CAS No.:
1879925-92-4 |
| Purity:
100% (SEC-HPLC) |
Supply Ability:
10g |
| Release date:
2026/07/09 |
Product Introduction
Bioactivity
| Name | Naxitamab |
| Description | Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting GD2 with antitumor activity, used to study neuroblastoma, osteosarcoma, and other GD2-positive cancers. |
| In vitro | Naxitamab (Hu3F8; 72 h) exhibits cytotoxicity against the neuroblastoma cell line LAN-1, with an EC50 value of 5.1 μg/mL[1].
Naxitamab (0.1-1 μg/mL; 4 h; peripheral blood mononuclear cells (PBMC) and polymorphonuclear leukocytes (PMN)) demonstrates antibody-dependent cell-mediated cytotoxic effects (ADCC)[1]. |
| In vivo | In athymic nude mice with LAN-1 xenografts, Naxitamab (Hu3F8; 100 mg/kg; intravenous; twice a week for 4 weeks) inhibits tumor growth in neuroblastoma xenografts[1]. |
| Storage | Store at low temperature
-20°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | Naxitamab |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States